HCPLive 5 Stories in Under 5: Week of 05/04
HCPLive
MAY 11, 2025
An audio recap of the top 5 stories in healthcare news from the week of 04/28-05/04.
Sun.May 11, 2025
59 
Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM
Circulation
MAY 11, 2025
Circulation, Volume 151, Issue 19 , Page e1001-e1001, May 13, 2025.
Omalizumab Side Effects in Patients With Chronic Urticaria Highlighted
HCPLive
MAY 11, 2025
This multinational, retrospective study highlights the effect of omalizumab on chronic urticaria among patients at multiple urticaria care centers.
Cell Type–Level Epigenetics at the Frontier of Atherosclerosis Research
Circulation
MAY 11, 2025
Circulation, Volume 151, Issue 19 , Page 1409-1411, May 13, 2025.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights from the CathPCI Registry
The American Journal of Cardiology
MAY 11, 2025
Publication date: Available online 10 May 2025 Source: The American Journal of Cardiology Author(s): Christina Lalani, Ravi K. Sharma, Jonathan Sevilla-Cazes, Kevin Kennedy, Neel M. Butala, Eric A. Secemsky, Duane Pinto, Marie-France Poulin, Roger Laham, Dhaval Kolte, David J. Cohen, Robert W.
Correction to: Sedentary Behavior and Light-intensity Physical Activity During Pregnancy and Cardiovascular Health: A Science Advisory From the American Heart Association
Circulation
MAY 11, 2025
Circulation, Volume 151, Issue 19 , Page e1000-e1000, May 13, 2025.
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
More Trending
Circulating mediators linking cardiometabolic diseases to HFpEF: a mediation Mendelian randomization analysis
Cardiovascular Diabetology
MAY 11, 2025
Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent clinical syndrome with high morbidity and mortality. Although HFpEF frequently coexists with cardiometabolic diseases, the ca.
Letter by Zhang et al Regarding Article, “Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study”
Circulation
MAY 11, 2025
Circulation, Volume 151, Issue 19 , Page e986-e987, May 13, 2025.
Association between cumulative changes of the triglyceride glucose index and incidence of stroke in a population with cardiovascular-kidney-metabolic syndrome stage 0–3: a nationwide prospective cohort study
Cardiovascular Diabetology
MAY 11, 2025
The triglyceride-glucose (TyG) index was associated with higher risk of mortality in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 03. However, the relationship between cumulative of.
Prompting Introspection
Circulation
MAY 11, 2025
Circulation, Volume 151, Issue 19 , Page 1375-1377, May 13, 2025.
Diabetes Dialogue: Tirzepatide vs Semaglutide for Obesity, Understanding SURMOUNT-5
HCPLive
MAY 11, 2025
Discover the latest findings on tirzepatide vs semaglutide for obesity treatment, highlighting significant weight loss results & clinical insights.
The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4
Circulation
MAY 11, 2025
Circulation, Volume 151, Issue 19 , Page 1430-1432, May 13, 2025.
SURMOUNT-5: Tirzepatide (Zepbound) Proves Benefit over Semaglutide (Wegovy) for Obesity
HCPLive
MAY 11, 2025
New data reveal tirzepatide significantly outperforms semaglutide in weight loss.
Response by Reitan et al to Letter Regarding Article, “Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study”
Circulation
MAY 11, 2025
Circulation, Volume 151, Issue 19 , Page e988-e989, May 13, 2025.
BMAL1 and HIF2α are key regulators of circadian-dependent variations in myocardial injury
Nature Reviews - Cardiology
MAY 11, 2025
Nature Reviews Cardiology, Published online: 12 May 2025; doi:10.1038/s41569-025-01169-4 A new study published in Nature reveals the role of the interaction between the circadian transcription factor BMAL1 and hypoxia-inducible factor 2 in circadian-dependent cardioprotection after ischaemiareperfusion injury, and highlights the potential of chronotherapeutic approaches for ischaemic heart disease.
Thalidomide, Hydroxyurea Combination Bests Hydroxyurea Alone for Sickle Cell Anemia
HCPLive
MAY 11, 2025
A mixture of thalidomide and hydroxyurea outperformed hydroxyurea alone in all primary outcomes.
Questions heart patients should ask before getting an MRI scan
Heart Sisters
MAY 11, 2025
When heart disease was the only serious diagnosis I had to think about, I rarely if ever thought about MRI scans…
Predicting ASCVD With Calprotectin
CardiacWire
MAY 11, 2025
Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early. Calprotectin is a protein released by white blood cells during inflammation, usually in the gastrointestinal tract. As a result, its commonly used to diagnose Crohns disease and ulcerative colitis, but hasnt been explored in CVD until now.
Let's personalize your content